Publisher
Springer Science and Business Media LLC
Reference10 articles.
1. Schettler V, Wieland E. [Effects of LDL-apheresis—more than reduction of cholesterol?]. Dtsch Med Wochenschr. 2007;132:575–8
2. Fischer S, Julius U, Tselmin S et al. [Lipoprotein(a): a risk factor for atherosclerosis]. Dtsch Med Wochenschr. 2014;139:1204–6
3. Jaeger BR, Richter Y, Nagel D et al. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med. 2009;6:229–39
4. Leebmann J, Roeseler E, Julius U et al. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study. Circulation. 2013;128:2567–76
5. Mellwig KP, Baller D, Gleichmann U et al. Improvement of coronary vasodilatation capacity through single LDL apheresis. Atherosclerosis 1998;139:173–8